[Effects of AG1478 on the expression of FOXM1 gene via FOXO3a in non-small cell lung cancer cells]
- PMID: 24314213
[Effects of AG1478 on the expression of FOXM1 gene via FOXO3a in non-small cell lung cancer cells]
Abstract
Objective: To explore the effects of EGFR-TKI AG1478 on the expression of FoxMl and FOXO3a genes in non-small cell cancer (NSCLC) cell lines, and explore the effect on cell proliferation and drug sensitivity to AG1478 after down-regulation of FOXMl and FOXO3a expression by RNAi technique.
Methods: Human lung cancer cells were treated with AG1478 at different concentrations. RT-PCR and Western blot were used to examine the expression of P-EGFR, FOXM1, FOXO3a mRNA and protein. After transient transfection of FOXM1 and FOXO3a siRNA, RT-PCR and Western blot were employed to determine the transfection efficiency and expression of the related proteins. CCK-8 assay, colony formation assay and flow cytometry were performed to evaluate the cell proliferation, colony formation ability and the changes in cell cycle distribution.
Results: The expressions of FOXM1 mRNA and protein were inhibited by AG1478 in a dose-dependent manner (both P < 0.05). After transfection with FOXM1 siRNA, the expressions of FOXM1 mRNA and protein, and proteins of cyclin B1, c-Myc, and Bcl-2 were significantly down-regulated, and the expressions of p21 and cleaved-PARP proteins were significantly up-regulated (all P < 0.05). The colony number of FOXM1siRNA transfection group was 37.3 ± 8.6, significantly lower than that of the blank control (135.3 ± 7.0) and negative control group (125.3 ± 7.5, P < 0.05). The colony formation inhibition rate was (7.40 ± 0.94)% in the negative control group and (72.4 ± 6.09)% in the FOXM1 siRNA transfection group. FOXM1siRNA transfection induced cell cycle arrest at G2/M phase with a percentage of (55.6 ± 4.83)%, significantly higher than that of the blank control [(24.30 ± 1.95)%] and negative control group [(21.3 ± 2.06)%, P < 0.05]. Additionally, the FOXM1siRNA transfection significantly increased the chemosensitivity of A549 cells to AG1478 (P < 0.05). Besides, AG1478 induced expression and nuclear relocation of FOXO3a. After the FOXO3a siRNA transfection, the expression of FOXM1 protein was significantly up-regulated, and resulted in a reduction of AG1478-induced inhibition of FOXM1.
Conclusions: The expression of FOXM1 is down-regulated by AG1478 via FOXO3a in the NSCLC cell lines, and then increases the chemosensitivity of A549 cells to AG1478. It suggests that FOXM1 could be a potential target for the therapy and drug exploitation for NSCLC.
Similar articles
-
[Role of inhibition of transcription factor forkhead box M1 expression by RNA interference in the proliferation and invasiveness of non-small cell lung cancer cells].Zhonghua Yi Xue Za Zhi. 2009 Sep 15;89(34):2424-8. Zhonghua Yi Xue Za Zhi. 2009. PMID: 20137699 Chinese.
-
Baicalein increases the expression and reciprocal interplay of RUNX3 and FOXO3a through crosstalk of AMPKα and MEK/ERK1/2 signaling pathways in human non-small cell lung cancer cells.J Exp Clin Cancer Res. 2015 May 7;34(1):41. doi: 10.1186/s13046-015-0160-7. J Exp Clin Cancer Res. 2015. PMID: 25948105 Free PMC article.
-
Casticin induces growth suppression and cell cycle arrest through activation of FOXO3a in hepatocellular carcinoma.Oncol Rep. 2013 Jan;29(1):103-8. doi: 10.3892/or.2012.2076. Epub 2012 Oct 9. Oncol Rep. 2013. PMID: 23064420
-
Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance.Curr Drug Targets. 2016;17(2):164-77. doi: 10.2174/1389450115666141122211549. Curr Drug Targets. 2016. PMID: 25418858 Free PMC article. Review.
-
Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance.Chin J Cancer. 2013 Jul;32(7):365-70. doi: 10.5732/cjc.012.10277. Epub 2013 May 27. Chin J Cancer. 2013. PMID: 23706767 Free PMC article. Review.
Cited by
-
MEK Inhibition Induces Canonical WNT Signaling through YAP in KRAS Mutated HCT-15 Cells, and a Cancer Preventive FOXO3/FOXM1 Ratio in Combination with TNKS Inhibition.Cancers (Basel). 2019 Feb 1;11(2):164. doi: 10.3390/cancers11020164. Cancers (Basel). 2019. PMID: 30717152 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous